Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS)

Medicare covers dermal injections for facial lipodystrophy syndrome only for HIV-infected beneficiaries when the LDS is caused by antiretroviral therapy and significantly contributes to the beneficiary's depression, and only when the dermal filler used is FDA-approved for LDS. Dermal fillers not FDA-approved for LDS, or use of fillers for indications other than LDS in this population, are not covered. Documentation should demonstrate HIV infection, LDS causation by antiretroviral therapy, the contribution of LDS to depression, product identification, and a date of service on or after March 23, 2010.

"Dermal injections are covered only when the dermal filler used is FDA-approved specifically for the treatment of facial lipodystrophy syndrome (LDS)."

Sign up to see full coverage criteria, indications, and limitations.